05 Apr LAKEWOOD-AMEDEX ENROLLS FIRST PATIENT IN PHASE 2 CLINICAL TRIAL FOR PATIENTS WITH CHRONIC DIABETIC FOOT ULCERS (cDFU)
Lakewood-Amedex’s Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022 SARASOTA, Fla., April 5, 2022 - Lakewood-Amedex, Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics...